Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin

Jamal Wadi Al Ramahi, Mustafa Ramadan, Waad Jaber, Lamya Abushanab, Mohammad Mughrabi, Noor Alshamayleh, Ahmad Mulhem, Dania Momani, Mohammad Obaidat, Ghayda Haddad, Basma Khalil, Anas Zahran, Esraa Odat, Nadeen Kufoof, Haneen Arabiat, Amr Diab, Antonio R Anzueto

Research output: Contribution to journalArticle

Abstract

Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.

Original languageEnglish (US)
Pages (from-to)878-886
Number of pages9
JournalJournal of Infection in Developing Countries
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Levofloxacin
Pneumonia
Fluoroquinolones
Multivariate Analysis
Anti-Infective Agents
Multicenter Studies
Diabetes Mellitus
Retrospective Studies
moxifloxacin
Bacteria

Keywords

  • CAP
  • Community-associated pneumonia
  • Levofloxacin
  • Moxifloxacin
  • Speed of recovery

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Infectious Diseases
  • Virology

Cite this

Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin. / Ramahi, Jamal Wadi Al; Ramadan, Mustafa; Jaber, Waad; Abushanab, Lamya; Mughrabi, Mohammad; Alshamayleh, Noor; Mulhem, Ahmad; Momani, Dania; Obaidat, Mohammad; Haddad, Ghayda; Khalil, Basma; Zahran, Anas; Odat, Esraa; Kufoof, Nadeen; Arabiat, Haneen; Diab, Amr; Anzueto, Antonio R.

In: Journal of Infection in Developing Countries, Vol. 12, No. 10, 01.10.2018, p. 878-886.

Research output: Contribution to journalArticle

Ramahi, JWA, Ramadan, M, Jaber, W, Abushanab, L, Mughrabi, M, Alshamayleh, N, Mulhem, A, Momani, D, Obaidat, M, Haddad, G, Khalil, B, Zahran, A, Odat, E, Kufoof, N, Arabiat, H, Diab, A & Anzueto, AR 2018, 'Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin', Journal of Infection in Developing Countries, vol. 12, no. 10, pp. 878-886. https://doi.org/10.3855/jidc.10335
Ramahi, Jamal Wadi Al ; Ramadan, Mustafa ; Jaber, Waad ; Abushanab, Lamya ; Mughrabi, Mohammad ; Alshamayleh, Noor ; Mulhem, Ahmad ; Momani, Dania ; Obaidat, Mohammad ; Haddad, Ghayda ; Khalil, Basma ; Zahran, Anas ; Odat, Esraa ; Kufoof, Nadeen ; Arabiat, Haneen ; Diab, Amr ; Anzueto, Antonio R. / Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin. In: Journal of Infection in Developing Countries. 2018 ; Vol. 12, No. 10. pp. 878-886.
@article{c33e88509cf14e2dbee3ccc91ab743c0,
title = "Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin",
abstract = "Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5{\%} males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9{\%} (95{\%} CI, 69.9 to 81.8), and 84.0{\%} (95{\%} CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1{\%}, 95{\%} CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9{\%}, (95{\%} CI, 88.3 – 95.6), and 95.5{\%} (95{\%} CI, 91.8-99.2) for moxifloxacin (difference-3.5{\%}, 95{\%} CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.",
keywords = "CAP, Community-associated pneumonia, Levofloxacin, Moxifloxacin, Speed of recovery",
author = "Ramahi, {Jamal Wadi Al} and Mustafa Ramadan and Waad Jaber and Lamya Abushanab and Mohammad Mughrabi and Noor Alshamayleh and Ahmad Mulhem and Dania Momani and Mohammad Obaidat and Ghayda Haddad and Basma Khalil and Anas Zahran and Esraa Odat and Nadeen Kufoof and Haneen Arabiat and Amr Diab and Anzueto, {Antonio R}",
year = "2018",
month = "10",
day = "1",
doi = "10.3855/jidc.10335",
language = "English (US)",
volume = "12",
pages = "878--886",
journal = "Journal of Infection in Developing Countries",
issn = "1972-2680",
publisher = "Journal of Infection in Developing Countries",
number = "10",

}

TY - JOUR

T1 - Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin

AU - Ramahi, Jamal Wadi Al

AU - Ramadan, Mustafa

AU - Jaber, Waad

AU - Abushanab, Lamya

AU - Mughrabi, Mohammad

AU - Alshamayleh, Noor

AU - Mulhem, Ahmad

AU - Momani, Dania

AU - Obaidat, Mohammad

AU - Haddad, Ghayda

AU - Khalil, Basma

AU - Zahran, Anas

AU - Odat, Esraa

AU - Kufoof, Nadeen

AU - Arabiat, Haneen

AU - Diab, Amr

AU - Anzueto, Antonio R

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.

AB - Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.

KW - CAP

KW - Community-associated pneumonia

KW - Levofloxacin

KW - Moxifloxacin

KW - Speed of recovery

UR - http://www.scopus.com/inward/record.url?scp=85061016270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061016270&partnerID=8YFLogxK

U2 - 10.3855/jidc.10335

DO - 10.3855/jidc.10335

M3 - Article

AN - SCOPUS:85061016270

VL - 12

SP - 878

EP - 886

JO - Journal of Infection in Developing Countries

JF - Journal of Infection in Developing Countries

SN - 1972-2680

IS - 10

ER -